Ichihara et al. analyzed 513 NSCLC patients using a BMI cut-off value of 22 kg/m2 and reported that no significant difference in the PFS and OS was observed between the high- and low-BMI patients with NSCLC (n = 84) harboring high PD-L1 expression (≥50%) and receiving first-line pembrolizumab; contrarily, the PFS and OS of high-BMI patients who received PD-1 blockade monotherapy as second- or later-line treatment was significantly longer than those of low BMI patients (PFS: 3.7 vs. 2.8 months, p = 0.036; OS: 15.4 vs. 13.5 months, p = 0.021) (n = 429) [27]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.